Signadori is advancing a platform designed to overcome the challenges of treating solid cancers
News
Teva and Fosun Pharma partner on early-stage oncology drug
The candidate is being evaluated as both a monotherapy and in combination pembrolizumab
FDA approves UroGen’s Zusduri to treat recurrent bladder cancer
Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US
EDX medical partners with spire healthcare to advance disease diagnostics
Collaboration aims to improve rapid detection and personalised treatments
Investigational treatment shows promise for aggressive multiple myeloma
Results suggest bispecific antibody combination could improve outcomes
Levicept presents new LEVI-04 data at EULAR
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen
Migraine takes the spotlight at European Parliament
EMHA calls for its inclusion in EU neurological health strategy
Bimekizumab shows lasting efficacy at EULAR 2025
Three-year data highlights inflammation control in psoriatic arthritis
Argenx presents new efgartigimod data at EULAR 2025
Rheumatology studies show promising results for Sjogren’s disease
Tagomics secures £860k grant for colorectal cancer test
Biotech firm to collaborate with NHS on early detection study
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
EC approves Santen’s Ryjunea to slow progression of paediatric myopia
Therapy indicated for children aged 3 to 14 at treatment initiation
Linear Diagnostics awarded £1m to develop rapid STI test
New funding supports development of diagnostic platform
NICE recommends Sogroya for growth hormone deficiency in children
Treatment provides option for children with growth failure
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
